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Summary The detection of 1,3-b-D-glucan serum levels may permit establishing the diagnosis of
invasive fungal infections more early. We tested in six healthy volunteers whether the
intake of a 1,3-b-D-glucan-containing nutritional supplement leads to false-positive
1,3-b-D-glucan levels. All levels were negative, even in two different dosing regimens.
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Background
Early diagnosis of invasive fungal infection (IFI) in
neutropenic subjects has the potential to increase anti-
fungal therapeutic response. Histopathological demon-
stration of organisms in tissue specimens or growth of
fungal agents in culture media is still the gold standard
method, but obtaining such specimensmay be difficult.1,2
1,3-b-D-glucan is part of the outer cell wall of
pathogenic fungi with the exception of Zygomycetes
and Cryptococcus species. Viruses, as well as human
cells, do not contain 1,3-b-D-glucan. Glucans are
released from fungal and bacterial cell walls into the
systemic circulation of patients with (invasive) infection.
It has been shown that 1,3-b-D-glucan determination,
when combined with risk stratification and imaging, is
useful in permitting the early diagnosis of IFI.1
Recently, a nutritional supplement ImunixX (ixX
Pharma) is promoted as dietary supplement to stimulate
and restore the immune system.3 This supplement will
be targeted by the company to, amongst other popula-
tions, haematological ⁄ oncological patients [personal
communication IS - ixX pharma]. The active substance
in ImunixX is 1,3-1,6-b-D-glucan (derived from the cell
wall of Pleurotis ostreatus).4
Detection of 1,3-b-D-glucan serum levels has been
shown to be a faster method than culture in the
diagnosis of IFI, but as for all immunological tests, some
non-specific cross-reactions have been reported. False-
positive results have been shown, amongst other
factors, in patients with bacterial infections, in patients
treated with immunological preparations such as albu-
mins or globulins or when cellulose membranes or
filters are used (i.e. during haemodialysis). In accor-
dance to false positivity reported with the galactoman-
nan test, false positivity could also expected in relation
to diet or the intake of dietary supplements.1 We
examined if the daily oral intake of the ImunixX dietary
supplement could lead to false-positive 1,3-b-D-glucan
levels leading to interference with the diagnosis of IFI.
Methods
The study was performed during a 7-day period in six
healthy volunteers (two male subjects, four female
subjects; mean age: 30 years). The volunteers were
randomly divided into two groups to test two different
dosing regimens, as recommended by the company, one
for treatment (high dose) and one for prophylaxis (low
dose).3 Three volunteers were taking the high-dose
regimen, i.e. 500 mg of 1,3-1,6-b-D-glucan daily during
5 days followed by 100 mg daily during 2 days. The
second group of three volunteers took 100 mg daily
during 7 days.
Three blood samples were taken from each volunteer.
The first sample was taken before the administration of
ImunixX (day 0), and the second and third samples
were taken, respectively, on days 5 and 7, 1 h after
ingestion. Samples were centrifuged and serum was
frozen at )20 C until analysis.
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The dietary supplement was ingested on an empty
stomach to avoid interaction with food. During the
study period, mushrooms were avoided to exclude false
positivity due to diet.
1,3-b-D-glucan levels were determined as previously
published using the Fungitell 1,3-b-D-glucan detection
assay (Associates of Cape Cod), which has been shown
to be a highly sensitive and specific diagnostic tool for
IFI, when a cut-off of serum 1,3-b-D-glucan level of 60
or 80 pg ml)1 is chosen.5,6 The Fungitell assay reacts
equally with both 1,3-b-D-glucan and 1,3-1,6-b-D-
glucan.5
The study was approved by the hospitals Ethics
Committee, and all participants signed the informed
consent.
Results and Discussion
1,3-b-D-glucan serum levels were negative in all volun-
teers during the period of intake of the ImmunixX
supplement, both in the high-dose and prophylactic-
dose regimens. In the low-dose group, mean levels [and
ranges] were 35.6 [6–84], 31.3 [21–50] and 20.3 [11–
38] pg ml)1, on days 0, 5 and 7 respectively. In the
high-dose regimen, mean levels [and ranges] were 26.5
[11–42], 16.3 [11–21] and 30.3 [10–45] pg ml)1 on
days 0, 5 and 7 respectively. Only in subject no. 6, the
day 0 sample was 84 pg ml)1. This elevated b-D-glucan
result cannot be easily clarified, maybe it was related to
the intake of other fungi-containing food, as only
mushrooms were restricted. However, a positive serum
level can also reflect an aspecific reaction. The specificity
of the Fungitell assay has been shown to be 92.5% in 40
healthy blood donors.7 It was certainly not related to
the intake of the ImunixX, as the sample was taken
before ingestion of the supplement.
During the last 20 years, several mushroom extracts,
containing amongst other substances b-D-glucans, were
promoted for their potential anticancer effects, such as
induction of apoptosis or modulation of the immune
response.8,9 Ruling out cross-reactivity with the 1,3-b-
D-glucan serological test is important, especially in this
setting where 1,3-b-D-glucan is used as a biomarker for
earlier diagnosis of IFI.
According to the product information of this specific
supplement, ImunixX stimulates the host immune
response by binding the M-cells (microfold cells) found
in the epithelium of the Peyers patches in the duode-
num. These M-cells are capable of transporting 1,3-1,6-
b-D-glucan across the epithelial barrier from the gut
lumen to the macrophages, leading to a stimulated
mucosal immunity.3
It seems from our results that ImunixX can probably
be safely used in patients with an intact mucosal barrier.
However, this should be interpreted with care, as this
was tested in only six volunteers, obviously the main
limitation of our study. Moreover, it remains unclear
whether these results can be extrapolated to patients
with mucositis or graft-vs.-host-disease, as the absorp-
tion of 1,3-1,6-b-D-glucan may be enhanced because of
increased gastrointestinal permeability.
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